Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02285647 · ClinicalTrials.gov registry record · Phase 1

An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant

A Phase 1 study, sponsored by Tesaro.

Completed
Registry status
Phase 1
Development phase
138
Enrollment target

NCT02285647: Completed Phase 1 study, sponsored by Tesaro.

NCT02285647 is a Phase 1 study that has completed, run by Tesaro. The registered enrollment target is 138 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (130% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02285647, a Phase 1 study, has completed, sponsored by Tesaro.

COMPLETED
Registry status
Phase 1
Development phase
138 participants
Enrollment target

Study Summary

This is an open-label, randomized, single-dose, single-center, parallel-group bioequivalence study of orally- and IV-administered rolapitant in healthy male and female subjects.

Interventions

  • DRUG Rolapitant - Oral
  • DRUG Rolapitant - IV

Trial Details

FieldValue
Enrollment Target 138 participants
Start Date 2014-09
Est. Completion 2015-05
Phase Phase 1
Tesaro

26 total trials

What the finished NCT02285647 record still lists

NCT02285647 is an interventional study that assigns participants to a tested intervention. The registered 138 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (130% higher).

The record links to 0 conditions, and to 2 interventions - of which Rolapitant - Oral is the first listed.

NCT02285647 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT02285647 about?

NCT02285647 is a clinical study titled "An Open-Label, Randomized, Pivotal, Bioequivalence Study of Oral and Intravenous Rolapitant". This is an open-label, randomized, single-dose, single-center, parallel-group bioequivalence study of orally- and IV-administered rolapitant in healthy male and female subjects.

What is the current status of trial NCT02285647?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 138 participants. The study started on 2014-09. Estimated completion is 2015-05.

What interventions are being tested in trial NCT02285647?

The interventions under investigation include: Rolapitant - Oral (DRUG), Rolapitant - IV (DRUG).

Who is sponsoring clinical trial NCT02285647?

This trial is sponsored by Tesaro, which has 26 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT02285647's enrollment target sits among peer trials

138 418th of 2000 higher than 1,581 of 2,000 other Phase 1 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04402788 · 138 participants · Phase 2

    Testing the Addition of Radiation Therapy to the Usual Immune Therapy Treatment (Atezolizumab) for Extensive Stage Small Cell Lung Cancer, The RAPTOR Trial

  • NCT04883255 · 138 participants · Early Phase 1

    Cannabis Use, Cognition, and the Endocannabinoid System in HIV

  • NCT05620784 · 138 participants · Phase 3

    Intra-operative Loop Diuretics to Improve Same-day Discharge Rates After HoLEP

  • NCT05832086 · 138 participants · Phase 2

    Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02285647, the US trial registry maintained by the National Library of Medicine. NCT02285647 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.